Introduction
Chronic obstructive pulmonary disease (COPD) is one of the most life-threatening diseases with high morbidity and mortality rates (1, 2) . It is estimated that 65 million people may suffer from moderate or severe COPD (3) . The prevalence of COPD ranges from 5.4-13.4% in Asian countries (4) . Disabilities as a result of COPD are predicted to be continuously increasing around the world (4) . Smoking cessation and supplemental oxygen are used to slow disease progression and decrease the mortality of COPD (5) . In addition, western medicines are also frequently applied in clinical treatment of COPD (6) . However, effects of these therapeutic measures are disappointing, and efforts to treat COPD need to be improved. Therefore, it is critical to identify novel strategies to prevent the development and progression of COPD. The improvement of lung function and quality of life, and reductions in symptoms and exacerbations will be the predominant focus in future management of COPD (7) .
Although the possible pathogenetic mechanisms of COPD have been widely explored, the holistic understanding of COPD remains largely unknown. It is evidenced that COPD is generally associated with inflammatory processes and oxidative stress (8, 9) . Inflammation-induced inflammatory mediators are involved in lesions of the airways, lung parenchyma and pulmonary vessels of patients with COPD (10) . Oxidative stress is one of the key components in the airflow limitation of patients with COPD (11, 12) . Oxidative stress is a major contributor to various pathogenic processes in the lungs (13) . Cigarette smoke and inflammatory cell-derived reactive oxygen species are critical for the increased oxidative stress in patients with COPD (12) . Depression of inflammation or oxidative stress may be important approaches for the treatment of COPD (14) .
Traditional Chinese Medicine (TCM) has been used as a therapeutic alternative for COPD and has been used in the treatment of various other diseases for many years (15) . TCM has recently been demonstrated to have therapeutic effects Effect of Pingchuan Guben decoction on patients with chronic obstructive pulmonary disease: Results from a randomized comparative effectiveness research trial for patients with COPD associated with improvement in lung function, clinical symptoms and quality of life (16) . The present study was designed to investigate the effects of Pingchuan Guben decoction on clinical symptoms, lung function, quality of life, inflammation and oxidative stress in patients with COPD.
Patients and methods
Patients. The present clinical study was approved by the Ethics Committee of Nanjing BenQ Hospital (Nanjing, China) and was conducted following the ethical standards for human experimentation (17) . Subjects provided written informed consent prior to initiation of the study. A total of 86 patients were enrolled from January 2013 and October 2015, 62 males (72.1%) and 24 females (27.9%). All experiments were performed in accordance with relevant guidelines and regulations. The authors were registered to perform all related trials. The present clinical research was a Phase II clinical trial (ChiCTR-TRC-15001143).
Inclusion and exclusion criteria. Patients were enrolled in the present study under the following inclusion criteria: i) Patients met the diagnostic criteria of global strategies for the diagnosis, management, and prevention of COPD reported by Global Initiative for Chronic Obstructive Lung Disease (GOLD) (18) ; ii) patients met TCM pattern criteria of stable or acute exacerbation COPD (19) ; iii) patients were aged between 40-75 years; iv) patients voluntarily participated in the study; v) patients completed and submitted the informed consent form; and vi) patients received no treatment for at least 2 weeks prior to participation in the study (1) . Patients were excluded from the present study for the following reasons: i) Patients had airflow limitation due to lung cancer, cystic fibrosis or other respiratory diseases; ii) patients suffered from acute heart failure, aplastic anemia, acute cerebral hemorrhage, coronary heart disease, diabetes, hypertension or other life-threatening diseases; iii) patients used immunosuppressive agent therapy within 2 weeks of study initiation; iv) female patients who were pregnant or breastfeeding; v) patients were allergic to western drugs or Chinese herbs used in the trial; and vi) patients received other medicinal interventions to treat COPD in the last 3 months prior to initiation of the study (20) .
Randomization and clinical treatment. The enrolled subjects were randomly allocated into two groups using ClinStat software (version 8.3.2; ClinStat, Chicago, IL, USA). Of the 86 enrolled patients, 43 patients were allocated to the control group and treated with western medicine. The patients were treated according to the Chinese Treatment Guidelines of COPD, as previously reported (10) . For patients in the control group with mild COPD, 200 inhalations of albuterol sulfate (inhalation aerosol; 100 µg/dose; Ventolin; GlaxoSmithKline, Brentford, UK) were used per day. For patients with moderate COPD, 60 inhalations of fumarate dehydrate (inhalation powder; 4.5 µg/dose; Oxis Turbohaler; AstraZeneca, Cambridge, UK) were used per day. For patients with severe COPD, 60 inhalations of salmeterol/fluticasone propionate (dry powder inhaler; 50 µg/dose; Seretide; GlaxoSmithKline) were used per day.
The remaining 43 cases were allocated to the intervention group and received western medicine plus TCM Pingchuan Guben decoction therapeutics. Pingchuan Guben decoction was composed of 15 g Salvia miltiorrhiza, 15 g suzi, 6 g Schisandra chinensis, 6 g agilawood, 6 g exocarpium citri, 12 g walnut, 12 g coltsfoot flower, 12 g Pinellia, 18 g magnetitum, 3 g Cordyceps sinensis and 3 g dried human placenta (Guizhou Sanli Pharmaceutical Co., Ltd., Guiyang, China). The mixture was dissolved in 500 ml water and evaporated to 150 ml. The patients were recommended to have 75 ml Pingchuan Guben decoction orally twice daily.
Primary endpoint. The primary endpoints for the present study were the clinical symptoms and the quality of life. The clinical efficacy was evaluated as previously reported (21) . When clini cal symptoms of COPD disappeared and total TCM syndrome scores reduced by 95-100%, the treatment was considered as clinical control and defined as I. When clinical symptoms of COPD disappeared and total TCM syndrome scores reduced by 75-96%, the treatment was recognized as significantly effective and set as II. If some clinical symptoms of COPD improved and total TCM syndrome scores reduced by 30-75%, the treatment was described as effective and defined as III. If clinical symptoms did not improve or even deteriorate, and total TCM syndrome scores decreased by <30%, the treatment was regarded as ineffective and defined as IV. The acute exacerbation of COPD was diagnosed based on the diagnostic criteria by GOLD and the Chinese Society of Respiratory Diseases (2007 version) (21) . The frequency and duration of acute exacerbation during the period of treatment were recorded for 12 weeks as previously described (19) . The general and mental health subscales in the Medical Outcomes 36-Item Short Form Health Survey (SF-36) and St. George's Respiratory Questionnaire (SGRQ) were adopted to estimate the quality of life in the two groups, as previously described (22) .
Pulmonary function and 6-min walking distance (6MWD).
The 6MWD was applied to assess the distance a person was able to walk on a flat surface within 6 min, which was measured before and after treatment. For evaluation of pulmonary function, forced vital capacity (FVC), forced expiratory volume in 1 sec (FEV1), FEV1/predicted value, FEV1/FVC, mean maximum expiratory flow (MMEF) 75/25 and peak expiratory flow (PEF) were also tested (21) .
TCM syndrome score evaluation. The assessment of TCM syndrome was carried out as previously described (23) , which was measured before and after treatment. The total score represented the severity of symptoms predominantly including cough, expectoration and shortness of breath. The severity of each symptom was divided into four degrees: A score of 0 indicated no symptom of COPD; a score of 2 represented mild symptoms of COPD; a score of 4 suggested moderate symptoms of COPD; and a score of 6 implied severe symptoms of COPD. The higher the total scores, the more serious the symptoms (21) .
Collection of sputum and serum samples. Sputum induction was obtained prior to and after 12 weeks of therapy. From all participants, 5 ml venous blood prior to and after treatment was drawn into serum tubes, clotted at room temperature for 30-60 min, and then centrifuged at 1,500 x g for 15 min at 4˚C. Serum samples were stored and frozen at -80˚C prior to analysis (23) .
Detection of inflammation-related factors.
Serum surfactant protein D (SP-D; cat. no. DSFPD0; R&D Systems, Inc., Minneapolis, MN, USA), procalcitonin (PCT; cat. no. O00214; RayBiotech Inc., Norcross, GA, USA), soluble triggering receptor expressed on myeloid cell-1 (sTREM-1; cat. no. MBS9310020; MyBioSource, Inc., San Diego, CA, USA), interferon-G induced protein 10 (IP-10; cat. no. HM2031. HyCult Biotech, Uden, The Netherlands) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL; cat. no. ABIN579401; Sciencell Research Laboratories, Carlsbad, CA, USA) levels were analyzed with commercial ELISA kits, following the manufacturer's protocols. Serum amylase A (SAA) was determined by an automatic chemistry analyzer (Vitros 3600; Johnson & Johnson, New Brunswick, NJ, USA).
Measurement of inflammation protease molecules.
The concentration of serum neutrophil elastase (NE) was determined with a commercial ELISA kit (cat. no. BMS269; Thermo Fisher Scientific, Inc., Waltham, MA, USA), following the manufacturer's instructions. ELISA was employed to detect secretory leukocyte protease inhibitor (SLPI; cat. no. DPI00) and tissue inhibitor of metalloproteinase 1 (TIMP-1; cat. no. DTM100) in both groups at the same period (R&D Systems, Inc.). Serum concentrations of serum α1-antitrypsin (α1-AT) were measured using nephelometry (OUVV15; Dade Behring Marburg GmbH, Frankfurt, Germany), according to the manufacturer's suggestions.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)
. mRNA expression levels of Kelch-like ECH-associated protein (Keap1) and nuclear factor-E2-related factor-2 (Nrf2) in induced sputum were quantified with a fluorescence quantitative PCR system (Roche Diagnostics, Basel, Switzerland). Briefly, total RNA was obtained using TRIzol reagent (Ambion; Thermo Fisher Scientific, Inc.) and cDNA was synthesized with a cDNA synthesis kit. (R222-01; Vazyme Biotech Co., Ltd., Nanjing, China) according to the manufacturer's instructions. The expression levels of target mRNA were determined by qPCR using a SYBR pre-mixed system (Q321-01; Vazyme Biotech Co., Ltd.) according to the manufacturer's instructions and specific primers. After being denatured at 94˚C for 5 min, the solution underwent PCR for targeted genes at 94˚C for 20 sec, 62˚C for 30 sec and 72˚C for 45 sec for 45 cycles. All experiments were conducted in triplicate in each sample, and the average cycle thresholds were used to determine fold-change using the 2 -ΔΔCq method (24) . The relative quantification of gene expression was reported as a relative quantity to the β-actin internal control value. The primer sequences used were as follows: Keap1, forward 5'-GGG TCC CCT ACA GCC AAG-3' and reverse 5'-TGG GGT TCC AGA AGA TAA GC-3'; Nrf2, forward 5'-ACA CGG TCC ACA GCT CAT C-3' and reverse 5'-TGC CTC CAA AGT ATG TCA ATC A-3'; and β-actin, forward 5'-CCA ACC GCG AGA AGA TGA-3' and reverse 5'-CCA GAG GCG TAC AGG GAT AG-3' .
Measurement of malondialdehyde (MDA), glutathione S-transferases (GST) and glutathione peroxidase (GPX) levels.
The MDA (A003-1, TBA method), GST (A061-1, Colorimetry) and GPX levels (A061-1, Colorimetry) in induced sputum were examined using commercial assay kits (Nanjing Jiancheng Bioengineering Institute, Nanjing, China), according to the manufacturer's protocols. The reactions were stopped with stop solution and read at 532 nm using a microtiter plate reader (ELX800; BioTek Instruments, Inc., Winooski, VT, USA). The MDA, GST and GPX levels were normalized to protein contents in induced sputum of each sample.
Measurement of superoxide anions. The level of superoxide anions in induced sputum was determined using a lucigenin-derived chemiluminescence method, as previously reported (25) . In brief, the superoxide anion level was measured based on the photon emission induced by dark-adapted lucigenin. (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). Light emission was detected 10 times in 10 min with the aid of a luminometer (20/20n; Turner BioSystems, Sunnyvale, CA, USA). The value of superoxide anion was described by mean light unit/min/mg protein.
Statistical analysis. All statistical analyses were performed using SPSS v. 19.0 (IBM Corp., Armonk, NY, USA). Quantitative data were presented as the mean ± standard deviation. Numerical data were expressed as constituent ratios. A single sample Kolmogorov-Smirnov non-parametric test was used to determine the uniformly of parameters. Student's t-tests and Fisher's exact tests were employed to compare the baseline characteristics between two groups. Paired t-tests were used for before and after treatment comparisons within the intervention and control groups, while independent samples t-tests or Mann-Whitney U tests were used based on data distribution to compare differences between two groups. The χ 2 test or Fisher's exact test was used to compare the proportion of categorical variables between two groups. P<0.05 was considered to indicate a statistically significant difference.
Results
Baseline data of the patients between two groups. A total of 91 patients with COPD were approached, of whom 86 conformed to the inclusion criteria. A total of 86 subjects with COPD were enrolled and agreed to participate and continue with this research (Fig. 1) . The patients were randomly allocated into each group (n=43 per group). There were no significant differences in baseline clinical data and demographics between the two groups ( Table I) .
Comparison of the clinical efficacy, and frequency and duration of acute exacerbation. Of 43 patients in the control group, the clinical efficacy rate was 25.6%, which was significantly lower than the value of 58.1% in the intervention group (P=0.002; Table II ). At the end of the 12 weeks, the average frequency (P=0.006) and duration (P=0.013) of acute exacerbation were significantly decreased in the intervention group compared with the control group (Table III) . In addition, the intervention group had a significantly lower number of patients that demonstrated acute exacerbation (P<0.001; Table III) . Table I . Baseline characteristics of the patients in the control and intervention groups. intervention group were significantly higher than those of the control group (Table IV) . However, there were no significant differences in MMEF75/25 or PEF between the two groups before or after treatment (P>0.05; Table IV) . Table III . Comparison of the frequency and duration of acute exacerbation in the control and intervention groups. 
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Comparison of total TCM syndrome score and quality of life.
There were no significant differences in total scores of TCM symptoms, SGRQ scores in each domain and SF-36 scores between the two groups before treatment. The TCM syndrome score, SF-36 scores and SGRQ score in respiratory symptoms, activity limitation, and the total score were significantly improved in both groups at the end of week 12 compared with the scores prior to treatment (all P<0.05; Table V) . However, the total scores of TCM symptoms, SGRQ scores and SF-36 scores in the intervention group were significantly improved compared with those in the control group after 12 weeks (all P<0.05; Table V) .
Comparisons of inflammation-related factors and protease molecules before and after treatment.
The expression levels of SP-D, PCT, sTREM-1, SAA, IP-10 and TRAIL, and the activities of NE, α1-AT, SLPI and TIMP-1 demonstrated no significant differences between the two groups before treatment. At 12 weeks, the levels of inflammation-related factors, including SP-D, PCT, sTREM-1, SAA, IP-10 and TRAIL (Fig. 2) , as well as protease molecules, such as NE, α1-AT, SLPI and TIMP-1 (Fig. 3) were all significantly ameliorated in both groups compared with 0 weeks (P<0.05). However, all levels and activities at 12 weeks were improved to a significantly greater extent in the intervention group compared with the control group (all P<0.05).
Comparison of the Kpeal1/Nrf2/antioxidant response element (ARE) pathway in induced sputum before and after treatment.
The differences in the mRNA expression levels of Keap1 and Nrf2, and the contents of superoxide anions, MDA, GST and GPX, in the induced sputum between the two groups were not significant prior to treatment (P>0.05; Fig. 4 ). The levels of Keap1, superoxide anions and MDA were significantly decreased, and the expression levels of Nrf2, GST, GPX were significantly increased in the two groups after 12 weeks of treatment compared with 0 weeks of treatment (P<0.05). However, the improvement in Keap1, Nrf2, superoxide anions, MDA, GST, GPX were improved to a significantly greater extent in the intervention group compared with those in the control group over the 12-week study period (P<0.05; Fig. 4 ).
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Discussion
COPD is considered as a systemic pulmonary inflammatory disease, which exerts a large threat to human physical and mental health in both developing and developed countries (26) . GOLD has predicted that COPD may gradually develop to the third greatest inducer of mortality by the year 2020 around the world (27) . TCM has recently demonstrated some advantages in improvements of clinical symptoms and reductions of the exacerbation incidence of COPD (28) . The present study demonstrated for the first time that combinations of western medicine with Pingchuan Guben decoction significantly ameliorated the clinical symptoms, reduced the frequency and duration of acute exacerbation, and improved the lung function and quality of life via regulation of inflammation mediators, protease molecules and activation of the Keap1/Nrf2 signaling pathway.
In China, many TCM modalities are commonly applied to prevent the development of COPD (29) . Comprehensive therapy based on TCM patterns lowered the frequency of acute exacerbation and alleviated the symptoms of patients with COPD (19) . Chinese medicine internal-external combined therapy markedly improved the scores of TCM syndrome and quality of life in patients with COPD (30) . In the present study, the results demonstrated that the clinical efficacy rate was significantly increased in patients with COPD who received the combination of western medicine and Pingchuan Guben decoction treatment. Combined use of western medicine and Pingchuan Guben decoction treatment also reduced the frequency and duration of acute exacerbation in patients with COPD. These results indicated that the western medicine and Pingchuan Guben decoction may be taken as an effective strategy for relieving clinical syndromes and enhancing the clinical effect in patients with COPD.
COPD exerts a substantial burden on the patients and public hospital service due to repeated symptoms (31) . The decrease in quality of life is closely related to individuals with COPD (15, 32, 33) . Scores for SF-36 or SGRQ are useful tools to assess the quality of life in patients with COPD (19) . TCM syndrome score is an indicator for evaluation of the degree of clinical syndrome in Chinese medicines (21) . Pulmonary dysfunction is clinically present as decreases in FEV1, FVC, FEV1 % and FEV1/FVC in patients with COPD (1). The 6 MWD is usually a good predictor of healthcare utilization in subjects with COPD (30) . Complementary and alternative medicines, including TCM, are used as a complement to western medical interventions of COPD therapy associated with improvement in lung function or quality of life (34) . In the present study, the results demonstrated that the mean values of 6 MWD, FEV1, FVC and FEV1/FVC in the intervention group were significantly higher than those of the control group at week 12. The TCM syndrome score, SF-36 scores and SGRQ score in respiratory symptoms, activity limitation and the total score were significantly improved in both groups at the end of week 12. However, there were significant differences in total scores of TCM symptoms SGRQ scores and SF-36 scores in the intervention group compared with those in the control group after 12 weeks. These results suggested that the combination of western medicine with Pingchuan Guben decoction was effective in improving lung function and quality of life of patients with COPD, and these improvements were greater than those seen with the use of western medicine alone.
Inflammation has an important role in the development and progression of COPD (35) . SP-D is positively asso ciated with the severity of COPD, and SP-D may successfully differentiate COPD from other respiratory symptoms or diseases (36) . Serum SP-D levels are remarkably increased in acute exacerbations of patients with COPD, and are negatively correlated with the lung function in COPD patients (37) . SP-D levels in the sputum may be considered as a valuable predictive indicator of prognosis of patients with COPD treated with inhaled corticosteroids and long-acting β2-agonists (38) . PCT is a precursor of the hormone calcitonin, and PCT is expressed in neuroendocrine cells of the intestine and the lung (39) . PCT has been proposed to have a prognostic importance in exacerbations of COPD (40, 41) . SAA is a member of the apolipoprotein family, which contributes to the aggravation of the inflammatory response through activation of neutrophil and other inflammatory cells (42, 43) . A previous study demonstrated that SAA levels are raised in inflammatory diseases, including COPD (44) . sTREM-1 is a triggering receptor of myeloid cells, is selectively expressed in neutrophils and is crucial for the activation of neutrophils (45) . IP-10 may induce the activation of monocytes and T lymphocytes, and is positively related to higher IL-6 levels in COPD. The accumulation of IP-10 predicates a poor outcome of treatment for patients with COPD (46) . Expression of TRAIL, a member of the tumor necrosis factor family, is markedly higher in COPD patients than in healthy controls (47) . Increased TRAIL levels were associated with lung dysfunction and systemic inflammation in patients with COPD (48) . NE belongs to the serine protease superfamily, and has a critical role in inflammatory damage and lung injury. NE is also vital for the induction of expressions of granulocyte stimulating factor and IL-6 (49). α1-AT is a type of protease inhibitor, which is responsible for the prevention of cathepsins release (50) . A previous study demonstrated that patients with α1-AT deficiency present higher NE levels and early formation of emphysema (51) . SLPI is recognized as a member of the whey acidic protein four-disulfide core family, and is abundantly produced by epithelial cells, neutrophils and macrophages in the digestive, respiratory and reproductive tracts (52) . The SLPI level is higher and is negatively correlated with FEV/FVC in patients with COPD (53) . A prospective study proposed that the expression of TIMP-1 in exhaled breath condensate is higher in patients with stable COPD (54) . The increased TIMP-1 expression is closely related with COPD exacerbation (54) . In the present study, it was demonstrated that the levels of inflammation-related factors, including SP-D, PCT, sTREM-1, SAA, IP-10 and TRAIL, as well as protease molecules such as NE, α1-AT, SLPI and TIMP-1, were significantly ameliorated in the intervention group compared with the control group at 12 weeks. These results indicated that combination of western medicine with Pingchuan Guben decoction effectively reduced the severity of systemic inflammation, and improved the ability of the body to clear the protease for effective inhibition of the inflammatory reaction.
Oxidative stress is a critical factor that is involved in the development of COPD (55, 56) . The systemic or local imbalance in oxidation/antioxidation is always presented in the acute exacerbation period and stable period of COPD (28) . The correction of oxidant/antioxidant imbalance has become a novel approach in the treatment of COPD (57) . The Keap1/Nrf2 signaling pathway has recently been demonstrated to be a defensive transduction pathway for the resistance to oxidation and chemical stimulation (58) . Nrf2 is dissociated from Keap1 to stabilize these antioxidant factors. Nrf2 is vital for the ARE-mediated expression of antioxidative enzymes, which has a protective role in the prevention of cell damage induced by oxidative stress (59) . Nrf2 and its gene targets are crucial endogenous antioxidative components against oxidative stress (60) . Keap1 is well known as an endogenous inhibitor of Nrf2 in the cytoplasm. Nrf2 dissociates from Keap1 under oxidative stress, which is a necessary step for the induction of various antioxidant genes, including GPX and GST (61) . The present results revealed that the levels of Keap1, superoxide anions and MDA were significantly decreased, and the expression of Nrf2, GST and GPX were significantly increased in the two groups after 12 weeks of treatment. However, the improvements in Keap1, Nrf2, superoxide anions, MDA, GST and GPX were greater in the intervention group than in the control group over the 12-week study period. These data indicated the key mechanisms involved in combination treatment using western medicine and Pingchuan Guben decoction for the treatment of COPD.
In conclusion, combinations of western medicine with Pingchuan Guben decoction may reduce the systemic inflammatory response and enhance antioxidant and anti-inflammatory function to effectively treat patients with COPD. In addition, multi-center, large-sample clinical trials are required for the measurement of long-term efficacy, safety and tolerability of Pingchuan Guben decoction.
